Industry drug development portfolio forecasting: productivity, risk, innovation, sustainability
Multiple factors may affect industry performance, risk, innovation and sustainability in coming years such as long-term economic trends, patents expiration, demographic shifts, and regulatory issues.
Currently available industry-wide prediction frameworks have limited capabilities. They are based on: (1) analysts’ consensus; (2) extrapolation of current trends; (3) financial performance of big pharma only; (4) empirical formulas, etc. Therefore, the need of robust forecasting methodology based on simulation modeling and covering the entire industry portfolio predictions could not be underestimated.
The simulation model utilizes available data about each drug/indication in the industry R&D pipeline, and transforms it using predictive simulation algorithms into a set of metrics characterizing future industry performance.
Industry-wide portfolio simulation model was developed to address short- and long-term portfolio productivity forecasting challenges. The model is drug–centric, it simulates drug development workflow process. The model also incorporates multiple business rules related to drugs interdependence.
The model predicted 2016 drop in NME approvals based on 2014 data. Other modeling experiments include analysis of industry sustainability and innovation strategy, impact of approval rates and likelihood on the variations of clinical trials cycle time, probabilities of success, and FDA approval cycle time.
Unless specified by prior arrangement, the author agrees to the following terms and assurances:
- For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
- I/we further give to the following assurances
- I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
- I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
- To the best of my/our knowledge, all the facts in the contribution are true and accurate;
- The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
- Nothing in the contribution is obscene or libellous;
- Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
- I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).